The Shield Multi-Cancer Detection (MCD) results report includes the following 10 cancers1:
Bladder
Liver (Hepatocellular)
Breast
Lung
CRC
Ovarian
Esophageal
Pancreatic
Gastric (Stomach)
Prostate
Overall performance: Shield MCD results report
overall sensitivity
(222/372)1
Stage I/II sensitivity1
Stage III/IV sensitivity1
specificity
(436/442)1
primary CSO
accuracy1,2
sensitivity in cancers without average-risk, standard-of-care screening1,3
Includes bladder, esophageal, gastric, hepatocellular, lung, ovarian, and pancreatic cancers.
sensitivity in the 6 most aggressive cancers (defined as the shortest survival rates)1,4
Includes esophageal, gastric, hepatocellular, lung, ovarian, and pancreatic cancers.
Ask your Shield representative for more information on the Shield MCD results report. Get in touch >
- Reference:
- 1. He Y, Forouzmand E, Burke J, et al. Validation of a plasma cell-free DNA methylation-based multi-cancer detection test. Abstract 10550. Presented at: 2025 ASCO Annual Meeting; May 30-June 3, 2025; Chicago, IL.
- 2. Data on file. Guardant Health, Inc.
- 3. US Preventive Services Task Force. Published recommendations, cancer. Accessed August 14, 2025. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results?topic_status=P&category%5B%5D=15&age_group%5B%5D=10&type%5B%5D=5&searchterm=
- 4. National Cancer Institute. Cancer stat facts: common cancer sites. Accessed August 14, 2025. https://seer.cancer.gov/statfacts/html/common.html